TG Therapeutics Inc (TGTX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Total Revenue Chart for TG Therapeutics Inc

TG Therapeutics Inc (TGTX) revenue for FY2025 was USD 616.3M, a 87.3% change from FY2024. TG Therapeutics Inc's revenue grew from USD 100.0K in 1996 to USD 616.3M in 2025 (616187.0% over 29 years). Earnings per share grew from USD 15.69 in 2010 to USD -1.35 in 2022 (-108.6%). Revenue compound annual growth rate: 5-year CAGR of 426.7%, 10-year CAGR of 129.4%, 20-year CAGR of 54.7%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.